|
1
|
Chamberlain MC: Treatment options for
glioblastoma. Neurosurg Focus. 20:E192006. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Chamberlain M: Evolving strategies: future
treatment of glioblastoma. Expert Rev Neurother. 11:519–532. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Schratter-Sehn AU and Marosi C: Treatment
of glioblastoma recurrences. Wien Med Wochenschr. 161:1–2. 2011.(In
German).
|
|
4
|
Kala M, Srámek V, Houdek M, Vaverka M and
Zmrzlík P: Treatment of glioblastoma multiforme. Cas Lek Cesk.
132:653–656. 1993.(In Czech).
|
|
5
|
Holland EC: Glioblastoma multiforme: the
terminator. Proc Natl Acad Sci USA. 97:6242–6244. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Yun TK, Lee YS, Lee YH, Kim SI and Yun HY:
Anticarcinogenic effect of Panax ginseng C.A. Meyer and
identification of active compounds. J Korean Med Sci. 16(Suppl):
S6–S18. 2001.
|
|
7
|
De Souza LR, Jenkins AL, Sievenpiper JL,
Jovanovski E, Rahelić D and Vuksan V: Korean red ginseng (Panax
ginseng C.A. Meyer) root fractions: differential effects on
postprandial glycemia in healthy individuals. J Ethnopharmacol.
137:245–250. 2011.
|
|
8
|
Varjas T, Nowrasteh G, Budán F, et al:
Chemopreventive effect of Panax ginseng. Phytother Res.
23:1399–1403. 2009. View
Article : Google Scholar
|
|
9
|
Helms S: Cancer prevention and
therapeutics: Panax ginseng. Altern Med Rev. 9:259–274.
2004.
|
|
10
|
Shin HR, Kim JY, Yun TK, Morgan G and
Vainio H: The cancer-preventive potential of Panax ginseng:
a review of human and experimental evidence. Cancer Causes Control.
11:565–576. 2000. View Article : Google Scholar
|
|
11
|
Attele AS, Wu JA and Yuan CS: Ginseng
pharmacology: multiple constituents and multiple actions. Biochem
Pharmacol. 58:1685–1693. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Yun TK: Experimental and epidemiological
evidence on non-organ specific cancer preventive effect of Korean
ginseng and identification of active compounds. Mutat Res.
523–524:63–74. 2003.PubMed/NCBI
|
|
13
|
Lu P, Su W, Miao ZH, Niu HR, Liu J and Hua
QL: Effect and mechanism of ginsenoside Rg3 on postoperative life
span of patients with non-small cell lung cancer. Chin J Integr
Med. 14:33–36. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ji C, Ren F and Xu M: Caspase-8 and
p38MAPK in DATS-induced apoptosis of human CNE2 cells. Braz J Med
Biol Res. 43:821–827. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kim HS, Lee EH, Ko SR, Choi KJ, Park JH
and Im DS: Effects of ginsenosides Rg3 and Rh2 on the proliferation
of prostate cancer cells. Arch Pharm Res. 27:429–435. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Youle RJ and Strasser A: The BCL-2 protein
family: opposing activities that mediate cell death. Nat Rev Mol
Cell Biol. 9:47–59. 2008. View
Article : Google Scholar : PubMed/NCBI
|
|
17
|
Fan TJ, Han LH, Cong RS and Liang J:
Caspase family proteases and apoptosis. Acta Biochim Biophys Sin
(Shanghai). 37:719–727. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Olsson M and Zhivotovsky B: Caspases and
cancer. Cell Death Differ. 18:1441–1449. 2011. View Article : Google Scholar
|
|
19
|
Cohen GM: Caspases: the executioners of
apoptosis. Biochem J. 326:1–16. 1997.
|
|
20
|
Raman M, Chen W and Cobb MH: Differential
regulation and properties of MAPKs. Oncogene. 26:3100–3112. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Seger R and Krebs EG: The MAPK signaling
cascade. FASEB J. 9:726–735. 1995.PubMed/NCBI
|
|
22
|
Roux PP and Blenis J: ERK and p38
MAPK-activated protein kinases: a family of protein kinases with
diverse biological functions. Microbiol Mol Biol Rev. 68:320–344.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zohrabian VM, Forzani B, Chau Z, Murali R
and Jhanwar-Uniyal M: Rho/ROCK and MAPK signaling pathways are
involved in glioblastoma cell migration and proliferation.
Anticancer Res. 29:119–123. 2009.PubMed/NCBI
|
|
24
|
Fang JY and Richardson BC: The MAPK
signalling pathways and colorectal cancer. Lancet Oncol. 6:322–327.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kolch W: Meaningful relationships: the
regulation of the Ras/Raf/MEK/ERK pathway by protein interactions.
Biochem J. 351:289–305. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Circu ML and Aw TY: Reactive oxygen
species, cellular redox systems, and apoptosis. Free Radic Biol
Med. 48:749–762. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Stadtman ER: Protein oxidation and aging.
Science. 257:1220–1224. 1992. View Article : Google Scholar
|
|
28
|
Stadtman ER: Role of oxidant species in
aging. Curr Med Chem. 11:1105–1112. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Kannan K and Jain SK: Oxidative stress and
apoptosis. Pathophysiology. 7:153–163. 2000. View Article : Google Scholar
|
|
30
|
Gomes A, Fernandes E and Lima JL:
Fluorescence probes used for detection of reactive oxygen species.
J Biochem Biophys Methods. 65:45–80. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Yue PY, Wong DY, Wu PK, et al: The
angiosuppressive effects of 20(R)- ginsenoside Rg3. Biochem
Pharmacol. 72:437–445. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Keum YS, Han SS, Chun KS, et al:
Inhibitory effects of the ginsenoside Rg3on phorbol
ester-induced cyclooxygenase-2 expression, NF-κB activation and
tumor promotion. Mutat Res. 523–524:75–85. 2003.
|
|
33
|
Lee JI, Ha YW, Choi TW, et al: Cellular
uptake of ginsenosides in Korean white ginseng and red ginseng and
their apoptotic activities in human breast cancer cells. Planta
Med. 77:133–140. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Christensen LP: Ginsenosides chemistry,
biosynthesis, analysis, and potential health effects. Adv Food Nutr
Res. 55:1–99. 2009.PubMed/NCBI
|
|
35
|
Xu TM, Cui MH, Xin Y, et al: Inhibitory
effect of ginsenoside Rg3 on ovarian cancer metastasis. Chin Med J
(Engl). 121:1394–1397. 2008.PubMed/NCBI
|
|
36
|
Liu TG, Huang Y, Cui DD, et al: Inhibitory
effect of ginsenoside Rg3 combined with gemcitabine on angiogenesis
and growth of lung cancer in mice. BMC Cancer. 9:2502009.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Henson JW: Treatment of glioblastoma
multiforme: a new standard. Arch Neurol. 63:337–341. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Wong ET and Yamaguchi NH: Treatment
advances for glioblastoma. Expert Rev Neurother. 11:1343–1345.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Yue TL, Ohlstein EH and Ruffolo RR Jr:
Apoptosis: a potential target for discovering novel therapies for
cardiovascular diseases. Curr Opin Chem Biol. 3:474–480. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Hickman JA: Apoptosis induced by
anticancer drugs. Cancer Metastasis Rev. 11:121–139. 1992.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Kerr JF, Wyllie AH and Currie AR:
Apoptosis: a basic biological phenomenon with wide-ranging
implications in tissue kinetics. Br J Cancer. 26:239–257. 1972.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Nagata S: DNA degradation in development
and programmed cell death. Annu Rev Immunol. 23:853–875. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Wieder R: TUNEL assay as a measure of
chemotherapy-induced apoptosis. Methods Mol Med. 111:43–54.
2005.PubMed/NCBI
|
|
44
|
He BC, Gao JL, Luo X, et al: Ginsenoside
Rg3 inhibits colorectal tumor growth through the down-regulation of
Wnt/β-catenin signaling. Int J Oncol. 38:437–445. 2011.PubMed/NCBI
|
|
45
|
Jiang JW, Chen XM, Chen XH and Zheng SS:
Ginsenoside Rg3 inhibit hepatocellular carcinoma growth via
intrinsic apoptotic pathway. World J Gastroenterol. 17:3605–3613.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Yuan HD, Quan HY, Zhang Y, Kim SH and
Chung SH: 20(S)-Ginsenoside Rg3-induced apoptosis in HT-29 colon
cancer cells is associated with AMPK signaling pathway. Mol Med
Rep. 3:825–831. 2010.PubMed/NCBI
|
|
47
|
Dhanasekaran DN and Johnson GL: MAPKs:
function, regulation, role in cancer and therapeutic targeting.
Oncogene. 26:3097–3099. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Kyriakis JM, App H, Zhang XF, et al: Raf-1
activates MAP kinase-kinase. Nature. 358:417–421. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Mavria G, Vercoulen Y, Yeo M, et al:
ERK-MAPK signaling opposes Rho-kinase to promote endothelial cell
survival and sprouting during angiogenesis. Cancer Cell. 9:33–44.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Allen CL and Bayraktutan U: Oxidative
stress and its role in the pathogenesis of ischaemic stroke. Int J
Stroke. 4:461–470. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Wiseman H and Halliwell B: Damage to DNA
by reactive oxygen and nitrogen species: role in inflammatory
disease and progression to cancer. Biochem J. 313:17–29.
1996.PubMed/NCBI
|
|
52
|
Bannister JV, Bannister WH and Rotilio G:
Aspects of the structure, function, and applications of superoxide
dismutase. CRC Crit Rev Biochem. 22:111–180. 1987. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Chelikani P, Fita I and Loewen PC:
Diversity of structures and properties among catalases. Cell Mol
Life Sci. 61:192–208. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Rhee SG, Chae HZ and Kim K:
Peroxiredoxins: a historical overview and speculative preview of
novel mechanisms and emerging concepts in cell signaling. Free
Radic Biol Med. 38:1543–1552. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Oberley TD and Oberley LW: Antioxidant
enzyme levels in cancer. Histol Histopathol. 12:525–535.
1997.PubMed/NCBI
|
|
56
|
Kong Q and Lillehei KO: Antioxidant
inhibitors for cancer therapy. Med Hypotheses. 51:405–409. 1998.
View Article : Google Scholar
|
|
57
|
Bechtel W and Bauer G: Catalase protects
tumor cells from apoptosis induction by intercellular ROS
signaling. Anticancer Res. 29:4541–4557. 2009.PubMed/NCBI
|
|
58
|
Zafarullah M, Li WQ, Sylvester J and Ahmad
M: Molecular mechanisms of N-acetylcysteine actions. Cell Mol Life
Sci. 60:6–20. 2003. View Article : Google Scholar
|
|
59
|
Aruoma OI, Halliwell B, Hoey BM and Butler
J: The antioxidant action of N-acetylcysteine: its reaction with
hydrogen peroxide, hydroxyl radical, superoxide, and hypochlorous
acid. Free Radic Biol Med. 6:593–597. 1989. View Article : Google Scholar : PubMed/NCBI
|
